Kodai Capital Management LP Purchases New Stake in Amicus Therapeutics, Inc. $FOLD

Key Points

• Kodai Capital Management LP has acquired 605,110 shares of Amicus Therapeutics, Inc. valued at approximately $4,938,000, representing about 0.20% ownership of the company.
• Multiple analysts have recently updated their ratings on Amicus Therapeutics, with Morgan Stanley upgrading the stock to "overweight" and UBS Group increasing its target price from $21.00 to $22.00.
• The stock opened at $7.59, with a market capitalization of $2.34 billion, and has a 52-week range between $5.51 and $12.65.

Kodai Capital Management LP purchased a new position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 605,110 shares of the biopharmaceutical company's stock, valued at approximately $4,938,000. Kodai Capital Management LP owned 0.20% of Amicus Therapeutics at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in FOLD. Virtus Fund Advisers LLC bought a new position in shares of Amicus Therapeutics during the fourth quarter valued at about $29,000. PNC Financial Services Group Inc. increased its stake in shares of Amicus Therapeutics by 211.4% in the first quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 3,497 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Amicus Therapeutics in the fourth quarter worth about $59,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Amicus Therapeutics during the first quarter valued at approximately $53,000. Finally, GAMMA Investing LLC grew its stake in Amicus Therapeutics by 1,610.8% during the first quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company's stock valued at $61,000 after acquiring an additional 7,007 shares in the last quarter.

Amicus Therapeutics Trading Up 1.2%

Shares of FOLD traded up $0.10 during mid-day trading on Thursday, reaching $7.95. The company's stock had a trading volume of 1,332,238 shares, compared to its average volume of 3,856,561. The company's fifty day moving average price is $6.66 and its two-hundred day moving average price is $7.09. Amicus Therapeutics, Inc. has a 52 week low of $5.51 and a 52 week high of $12.65. The company has a current ratio of 3.21, a quick ratio of 2.29 and a debt-to-equity ratio of 1.92. The stock has a market cap of $2.45 billion, a PE ratio of -66.20 and a beta of 0.55.

Analysts Set New Price Targets

A number of equities analysts have commented on FOLD shares. Morgan Stanley raised shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research note on Thursday, July 17th. Wall Street Zen cut shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, August 30th. Eight analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Amicus Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $16.22.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.